News and Updates

Dianthus Therapeutics stock surges as the company launches a pivotal Phase 3 clinical trial for its lead autoimmune drug candidate. Read the latest update.

Argo Biopharma has dosed the first patient in a Phase I trial for BW-41012, a novel siRNA therapy targeting Factor XI for safer anticoagulant treatment.

Merck and NMIMS join forces to launch the CATALYST programme, an industry-ready initiative designed to train the next generation of pharmaceutical experts.

OKYO Pharma files its annual report, confirming a stable cash position and detailing strategic plans to advance Phase 3 clinical trials for ocular therapy.

New research confirms that decentralized clinical trials improve patient access and diversity by removing geographic barriers to medical research.

Armata Pharmaceuticals advances AP-SA02 toward Phase 3, hitting key clinical and manufacturing milestones to combat resistant Staphylococcus aureus infections.

Bayer and Henry Ford Health have joined forces to broaden access to clinical trials, aiming to accelerate medical research and improve patient diversity.

New research shows bioavailable CurcuBoost curcumin significantly reduces knee osteoarthritis symptoms. Discover the latest findings on this adjunct therapy.

Bayer and Henry Ford Health have partnered to accelerate clinical trial access, leveraging EHR technology to improve research participation and patient care.

Discover the hidden operational and patient-care challenges at investigative sites when corporate acquisitions trigger the sudden closure of Phase 3 trials.